(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 16 August 2016- Actelion Ltd (SIX: ATLN) announced today that Swissmedic has granted approval for the orally active, selective IP prostacyclin receptor agonist Uptravi (selexipag), originally discovered and synthesized by Nippon Shinyaku, for patients with PAH in Switzerland. Uptravi is indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with advanced functional limitation (NYHA-functional class III/IV) to delay disease progression. Uptravi is effective in combination with an endothelin receptor antagonist (ERA) or a phosphodiesterase-5 (PDE-5) inhibitor, or in triple combination with an ERA and a PDE-5...
↧